Asthma

Future directions

Patricia Leonard, Sanjiv Sur

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Asthma continues to be a significant health care problem, as reflected by the increasing rise in disease morbidity and mortality. Because steroids are relatively safe, clinically effective, and easy to administer, they remain the gold standard of treatment. After many decades of use, however, it is apparent that inhaled corticosteroids have failed to halt the progression of the asthma epidemic. Newer, more effective drugs are being developed to combat this disease, and the interest in developing new medications to treat allergic disease and asthma has increased exponentially. The financial burden of asthma has also been a significant motivating factor in the development of new medications. It is estimated that in 1998 the total cost of asthma on society was $11 billion [175]. This consideration has further intensified the quest to develop more effective asthma medications. Table 1 reviews the wide array of drugs currently being investigated. With the development and approval of novel asthma treatments, millions of asthma sufferers will undoubtedly have increased therapeutic options for control of their disease in the near future.

Original languageEnglish (US)
Pages (from-to)1131-1156
Number of pages26
JournalMedical Clinics of North America
Volume86
Issue number5
DOIs
StatePublished - Sep 2002

Fingerprint

Asthma
Direction compound
Pharmaceutical Preparations
Adrenal Cortex Hormones
Steroids
Morbidity
Delivery of Health Care
Costs and Cost Analysis
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Asthma : Future directions. / Leonard, Patricia; Sur, Sanjiv.

In: Medical Clinics of North America, Vol. 86, No. 5, 09.2002, p. 1131-1156.

Research output: Contribution to journalArticle

Leonard, Patricia ; Sur, Sanjiv. / Asthma : Future directions. In: Medical Clinics of North America. 2002 ; Vol. 86, No. 5. pp. 1131-1156.
@article{931779c106a44b0a8690d47b77dccf8b,
title = "Asthma: Future directions",
abstract = "Asthma continues to be a significant health care problem, as reflected by the increasing rise in disease morbidity and mortality. Because steroids are relatively safe, clinically effective, and easy to administer, they remain the gold standard of treatment. After many decades of use, however, it is apparent that inhaled corticosteroids have failed to halt the progression of the asthma epidemic. Newer, more effective drugs are being developed to combat this disease, and the interest in developing new medications to treat allergic disease and asthma has increased exponentially. The financial burden of asthma has also been a significant motivating factor in the development of new medications. It is estimated that in 1998 the total cost of asthma on society was $11 billion [175]. This consideration has further intensified the quest to develop more effective asthma medications. Table 1 reviews the wide array of drugs currently being investigated. With the development and approval of novel asthma treatments, millions of asthma sufferers will undoubtedly have increased therapeutic options for control of their disease in the near future.",
author = "Patricia Leonard and Sanjiv Sur",
year = "2002",
month = "9",
doi = "10.1016/S0025-7125(02)00037-8",
language = "English (US)",
volume = "86",
pages = "1131--1156",
journal = "Medical Clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Asthma

T2 - Future directions

AU - Leonard, Patricia

AU - Sur, Sanjiv

PY - 2002/9

Y1 - 2002/9

N2 - Asthma continues to be a significant health care problem, as reflected by the increasing rise in disease morbidity and mortality. Because steroids are relatively safe, clinically effective, and easy to administer, they remain the gold standard of treatment. After many decades of use, however, it is apparent that inhaled corticosteroids have failed to halt the progression of the asthma epidemic. Newer, more effective drugs are being developed to combat this disease, and the interest in developing new medications to treat allergic disease and asthma has increased exponentially. The financial burden of asthma has also been a significant motivating factor in the development of new medications. It is estimated that in 1998 the total cost of asthma on society was $11 billion [175]. This consideration has further intensified the quest to develop more effective asthma medications. Table 1 reviews the wide array of drugs currently being investigated. With the development and approval of novel asthma treatments, millions of asthma sufferers will undoubtedly have increased therapeutic options for control of their disease in the near future.

AB - Asthma continues to be a significant health care problem, as reflected by the increasing rise in disease morbidity and mortality. Because steroids are relatively safe, clinically effective, and easy to administer, they remain the gold standard of treatment. After many decades of use, however, it is apparent that inhaled corticosteroids have failed to halt the progression of the asthma epidemic. Newer, more effective drugs are being developed to combat this disease, and the interest in developing new medications to treat allergic disease and asthma has increased exponentially. The financial burden of asthma has also been a significant motivating factor in the development of new medications. It is estimated that in 1998 the total cost of asthma on society was $11 billion [175]. This consideration has further intensified the quest to develop more effective asthma medications. Table 1 reviews the wide array of drugs currently being investigated. With the development and approval of novel asthma treatments, millions of asthma sufferers will undoubtedly have increased therapeutic options for control of their disease in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0036710089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036710089&partnerID=8YFLogxK

U2 - 10.1016/S0025-7125(02)00037-8

DO - 10.1016/S0025-7125(02)00037-8

M3 - Article

VL - 86

SP - 1131

EP - 1156

JO - Medical Clinics of North America

JF - Medical Clinics of North America

SN - 0025-7125

IS - 5

ER -